| 名稱 | NCOA4-RET/BaF3 |
| 型號(hào) | CBP73265 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | NCOA4-RET/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- BRAF系列標(biāo)準(zhǔn)品
- 【靶點(diǎn)模型+診斷質(zhì)控】BTK C481S的藥物開(kāi)發(fā)和診斷
- NCRI：新型檢測(cè)技術(shù)或能提前8年診斷出食管癌
- BCMA靶點(diǎn)藥物細(xì)胞篩選模型
- 心衰治療靶點(diǎn)：BNP/NPR1
- 大腦中新發(fā)現(xiàn)的一種淋巴細(xì)胞，能夠清除大腦廢物
- CD27細(xì)胞篩選模型
- TROP2靶點(diǎn)藥物爆發(fā)，診斷質(zhì)控緊跟步伐--科佰TROP2 IHC質(zhì)控品上新
- atcc細(xì)胞購(gòu)買(mǎi)途徑如何分辨清楚？
- 淺談NTRK fusion
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73265NCOA4-RET/BaF3
- 詳細(xì)內(nèi)容
| CBP73265 | |
| I. Introduction | |
Cell Line Name： | NCOA4-RET/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS1640+10%FBS |
Mycoplasma Status: | Negative |
| II.Background | |
NCOA4, nuclear receptor coactivator 4, is an androgen receptor coactivator (PMID: 15166229) and autophagy receptor that degrades ferritin complexes (PMID: 31061094) and plays a role in iron homeostasis (PMID: 30930742). NCOA4 fusions are frequently observed with RET in papillary thyroid carcinoma (also referred to as RET/PTC3) (PMID: 25731779) and have been reported in salivary intraductal carcinoma (PMID: 31162284), spindle cell tumors (PMID: 30938880), breast cancer (PMID: 30446652), colorectal cancer (PMID: 30210625), and lung cancer (PMID: 30038711). | |
| III. Representative Data | |
1. WB of NCOA4-RET/BaF3
| |
2. Anti-proliferation assay | |
Figure 2. CTG assay of for NCOA4-RET/BaF3 Stable Cell Line. | |
會(huì)員_a.png)